Cancer Immunology, Immunotherapy

, Volume 55, Issue 12, pp 1553–1564 | Cite as

Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer

  • Paal F. Brunsvig
  • Steinar Aamdal
  • Marianne K. Gjertsen
  • Gunnar Kvalheim
  • Carrie J. Markowski-Grimsrud
  • Ingunn Sve
  • Marianne Dyrhaug
  • Sissel Trachsel
  • Mona Møller
  • Jon A. Eriksen
  • Gustav GaudernackEmail author
Original Article


Purpose: A phase I/II study was conducted to investigate the safety, tolerability and clinical response to vaccination with a combination of telomerase peptides GV1001 (hTERT: 611–626) and HR2822 (hTERT: 540–548) in patients with non-small cell lung cancer. Experimental design: Twenty-six patients with non-small cell lung cancer received intradermal administrations of either 60 nmole (112 μg) or 300 nmole (560 μg) GV1001 in combination with 60 nM (68.4 μg) HR2822 and granulocyte macrophage-colony stimulating factor. The treatment period was 10 weeks. Booster vaccinations with 300 nM GV1001 were offered as follow-up. Monitoring of blood samples, clinical examination and radiological staging were performed regularly. Immune responses were measured as delayed-type hypersensitivity skin reaction and in vitro T cell proliferation. Bone marrow function was monitored in long time survivors. Results: The treatment was well tolerated with minor side effects. No bone marrow toxicities were observed in long time survivors with immune responses. Immune responses against GV1001 were detected in 11 of 24 evaluable patients during the primary regimen and in additional two patients following booster injections. Two patients responded to HR2822. Cloned GV1001-specific CD4+ T cells displayed a Th1 cytokine profile and recognized autologous antigen presenting cells pulsed with recombinant telomerase protein. A complete tumor response was observed in one patient who developed GV1001-specific cytotoxic T cells that could be cloned from peripheral blood. Conclusion: The results demonstrate that GV1001 and HR2822 are immunogenic and safe to use in patients with NSCLC. Induction of GV1001-specific immune responses may result in objective tumor responses. Based on these initial encouraging results, further clinical studies of GV1001 in NSCLC patients are warranted.


Clinical trial hTERT vaccine Promiscuous Th epitope NSCLC 



We thank Kari Lislerud for excellent technical assistance, and Mericon AS for monitoring of the study. This work has been supported by grants from The Norwegian Cancer Society (IS), the Norwegian Research Council and was supported by GemVax AS.


  1. 1.
    Shepherd F, Carney D (2000) In: Hansen H (ed) Treatment of NSCLC in Textbook of lung cancer. Martin DunitzGoogle Scholar
  2. 2.
    Pfister D, Johnson D, Azzoli C, et al. (2004) American Society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. JCO 22:330–353CrossRefGoogle Scholar
  3. 3.
    Woo Ey, Yeh H, Chu S, et al. (2002) Cutting edge; regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168:4272–4276PubMedGoogle Scholar
  4. 4.
    Hege K, Carbone D (2003) Lung cancer vaccines and gene therapy. Lung Cancer 41:S103–S113CrossRefPubMedGoogle Scholar
  5. 5.
    Autexier C (1999) Telomerase as a possible target for anticancer therapy. Chem Biol 6:R299–R303CrossRefPubMedGoogle Scholar
  6. 6.
    Fujita Y, Fujikane T, Fujiuchi, et al. (2003) The diagnostic and prognostic relevance of Human Telomerase reverse transcriptase mRNA expression detected in situ in patients with nonsmall cell lung carcinoma. Cancer 298:1008–1013CrossRefGoogle Scholar
  7. 7.
    Vonderheide RH, Hahn WC, Schultze JL, et al. (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673–679CrossRefPubMedGoogle Scholar
  8. 8.
    Minev B, Hipp J, Firat H, et al. (2000) Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 97:4796–4801CrossRefPubMedGoogle Scholar
  9. 9.
    Vonderheide RH, Anderson KS, Hahn WC, et al. (2001) Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 7:3343–3348PubMedGoogle Scholar
  10. 10.
    Arai J, Yasukawa M, Ohminami H, et al. (2001) Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 97:2903–2907CrossRefPubMedGoogle Scholar
  11. 11.
    Hernandez J, Garcia-Pons F, Lone YC, et al. (2002) Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci USA 99:12275–12280CrossRefPubMedGoogle Scholar
  12. 12.
    Scardino A, Gross DA, Alves P, et al. (2002) HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168:5900–5906PubMedGoogle Scholar
  13. 13.
    Gross DA, Graff-Dubois S, Opolon P, et al. (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113:425–433CrossRefPubMedGoogle Scholar
  14. 14.
    Schroers R, Huang XF, Hammer J, et al. (2002) Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res 62:2600–2605PubMedGoogle Scholar
  15. 15.
    Schroers R, Shen L, Rollins L, et al. (2003) Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 9:4743–4755PubMedGoogle Scholar
  16. 16.
    Uchida N, Otsuka T, Shigematsu H, et al. (1999) Differential gene expression of human telomerase-associated protein hTERT and TEP1 in human hematopoietic cells. Leuk Res 23:1127–1132CrossRefPubMedGoogle Scholar
  17. 17.
    Tahara H, Yasui W, Tahara E, et al. (1999) Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 18:1561–1567CrossRefPubMedGoogle Scholar
  18. 18.
    Gjertsen MK, Buanes T, Rossland AR, et al. (2001) Intradermal RAS peptide vaccination with granulocyte-macrophage colony-stimulation factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92:441–450CrossRefPubMedGoogle Scholar
  19. 19.
    Vonderheide RH, Domchek SM, Schultze JL, et al. (2004) Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res 10:828–839CrossRefPubMedGoogle Scholar
  20. 20.
    Ostrand-Rosenberg S (2005) CD4+ lymphocytes: a critical component of antitumor immunity. Cancer Invest 23:413–419CrossRefPubMedGoogle Scholar
  21. 21.
    Mountain C, Dresler C (1997) Regional lymph node classification for lung cancer staging. Chest 111:1718–1723PubMedCrossRefGoogle Scholar
  22. 22.
    Gjertsen MK, Saeterdal I, Saeboe-Larssen S, Gaudernack G (2003) HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes. J Mol Med 81:43–50PubMedGoogle Scholar
  23. 23.
    Testa NG, Molineux G (1993) Haematopoiesis: A practical approach, Volume 1, and First Edition. Oxford University Press, OxfordGoogle Scholar
  24. 24.
    Sutherland HJ, Eaves CJ, et al. (1991) Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells. Blood 3:666–672Google Scholar
  25. 25.
    Pettengell R, Luft T, et al. (1994) Direct comparison by limiting dilution analysis of long-term culture initiating cells in human bone marrow, umbilical cord blood, and blood stem cells. Blood 11:3653–3859Google Scholar
  26. 26.
    Rusten LS, Jacobsen SE, et al. (1994) Functional differences between CD38- and DR-subfractions of CD34+ bone marrow cells. Blood 84:1473–1481PubMedGoogle Scholar
  27. 27.
    Danet-Desnoyers GA, Luongo JL, Bonnet DA, Domcheck SM, Vonderheide RH (2005) Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Exp Hematol 33:1275–1280CrossRefPubMedGoogle Scholar
  28. 28.
    Sorensen JB, Hansen HH, Hansen M, et al. (1988) Brain metastasis in adenocarcinoma of the lung; frequency, risk groups, and prognosis. J Clin Oncol 6:1479–1480Google Scholar
  29. 29.
    Cibotti R, Kanellopoulos JM, Cabaniols J-P, et al. (1992) Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Nati Acad Sci USA 89:416–420CrossRefGoogle Scholar
  30. 30.
    Gross DA, Graff-Dubois S, Opolon P, et al. (2004) High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 113:425–433CrossRefPubMedGoogle Scholar
  31. 31.
    Parkhurst M, Riley J, et al. (2004) Immunization of patients with hTERT: 540–548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing Telomerase. Clin Cancer Res 10:4688–4698CrossRefPubMedGoogle Scholar
  32. 32.
  33. 33.
    Hirschowitz E, Foody T, Yanelli J, et al. (2004) Autologous dendritic cell vaccines for non-small cell lung cancer. JCO 22:2808–2815CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Paal F. Brunsvig
    • 1
  • Steinar Aamdal
    • 1
  • Marianne K. Gjertsen
    • 1
  • Gunnar Kvalheim
    • 1
  • Carrie J. Markowski-Grimsrud
    • 1
  • Ingunn Sve
    • 1
  • Marianne Dyrhaug
    • 1
  • Sissel Trachsel
    • 1
  • Mona Møller
    • 2
  • Jon A. Eriksen
    • 2
  • Gustav Gaudernack
    • 1
    • 3
    Email author
  1. 1.Norwegian Radium HospitalUniversity of OsloOsloNorway
  2. 2.GemVax ASOsloNorway
  3. 3.Gustav Gaudernack, Head of Section for Immunotherapy, Institute for Cancer Research The Norwegian Radium HospitalOsloNorway

Personalised recommendations